Savara Inc. SVRA
4.64 USD -0.08 (-1.69%)
Regular-session close
4.70 +0.06 +1.29%
After hours · Nov 13, 6:50 PM ET
4.58 Day range 4.84
4.17 52-week range 6.94
- YTD
- -23.05%
- 1 year
- +8.92%
News
seekingalpha.com Savara: The Market May Be Overestimating Its FDA Risk Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a pivotal FDA decision on November 22. SVRA's investment thesis hinges on strong clinical efficacy…
businesswire.com Savara Announces New Employment Inducement Grant YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new…
benzinga.com HC Wainwright & Co. Assumes Savara at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Matthew Caufield assumes Savara (NASDAQ:SVRA) with a Buy rating and announces Price Target of $10.- benzinga.com Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The…